Black Rock Inc. Brooklyn Immuno Therapeutics, Inc. Transaction History

Black Rock Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.23 - $0.71 $127,171 - $392,573	-552,920 Reduced 45.65%	658,302 $162,000
Q2 2022 Aug 12, 2022	SELL	$0.48 - $2.03 $563,918 - $2.38 Million	-1,174,831 Reduced 49.24%	1,211,222 $626,000
Q1 2022 May 12, 2022	BUY	$1.76 - $4.84 $419,415 - $1.15 Million	238,304 Added 11.1%	2,386,053 $4.89 Million
Q4 2021 Feb 10, 2022	BUY	$4.17 - $9.79 $1.51 Million - $3.54 Million	361,682 Added 20.25%	2,147,749 $8.96 Million
Q3 2021 Nov 09, 2021	BUY	$8.86 - $17.05 $3.39 Million - $6.53 Million	383,176 Added 27.31%	1,786,067 $16.6 Million
Q2 2021 Aug 11, 2021	BUY	$3.75 - $78.5 $5.26 Million - $110 Million	1,402,891 New	1,402,891 $25.3 Million

1.21M

Ticker BTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,825,700
Description
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy techno...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.